Eli Lilly is also developing another GLP-1 that is distinct from the Amylin products.
If you want an investment play on diabetes you might look at Amylin (NASDAQ: AMLN).
Amylin and Lilly have also been working together toward the approval of a successor drug, Bydureon.
FORBES: Diabetes Market Booms As Substitutes Sought For Daily Insulin Dosing
The deal will also help Amylin develop a sales force ahead of the launch of Symlin.
Farmer points to the fact that Lilly and Amylin are splitting profits, not merely sales.
Amid the delay, the partnership between Lilly and Amylin deteriorated, and ultimately was terminated.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Shares of Amylin and Alkermes were halted Friday in advance of the agency decision.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
For more on David Kliff's recommendation of Amylin, click here to watch a video.
Early clinical data for another Amylin candidate, Pramlintide, also shows potential for use as a weight-loss agent.
Scientists from Amylin saw Eng present his data at a 1996 diabetes conference and licensed his research.
Another rival drug to watch is Byetta, an already approved treatment from Amylin Pharmaceuticals and Eli Lilly.
Going forward, a joint committee of representatives from Lilly and Amylin will oversee the development of AC2993.
Bydureon is an injectable, extended-release version of Amylin's older diabetes drug, Byetta, which is injected twice daily.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Amylin and Lilly were optimistic they would get FDA approval later in 2010 after providing the requested information.
WSJ: FDA Approves Amylin's Bydureon Diabetes Drug After Delays
Reader and biotech investor Matthew Shulman wrote in a several week ago with this question about Amylin Pharmaceuticals.
Upside is possible for Gilead, Genentech and Amylin Pharmaceuticals (nasdaq: AMLN - news - people ).
Amylin sells a diabetes drug, Byetta, with Eli Lilly (nyse: LLY - news - people ).
In the case of Byetta, shares of Amylin dropped more than 6% on the day of the approval announcement.
Shares of Amylin are down more than 35% in the past 12 months.
After the divorce is finalized, he adds, Amylin will increase its sales staff to 715, up from 350 reps now.
Six months after a bitter dispute led to an unusual court battle, Eli Lilly and Amylin Pharmaceuticals are getting divorced.
Amylin Pharmaceuticals (AMLN), Xoma (XOMA) and Jazz Pharmaceuticals (JAZZ) are among companies selling stock to raise cash in recent weeks.
Because LAR would require less frequent injections--perhaps twice a month--Kliff believes this version to be the real blockbuster in Amylin's pipeline.
Recently, Amylin CEO Daniel Bradbury hinted that his diabetes drug Bydureon may have partly been a victim of the Avandia fall-out.
Ginger Graham , Amylin's chief executive, says that by educating doctors about GLP-1, she thinks Merck and Novartis might actually benefit Byetta.
Lilly and Amylin had to tell doctors to stop prescribing it to new patients until a new plant came online this September.
Two weeks ago, for instance, Bristol Myers Squibb acquired Amylin Pharmaceuticals (NASDAQ:AMLN), which has won approval for two diabetes drugs, BYETTA and SYMLIN.
The split, of course, puts to rest long-standing speculation that Lilly might simply buy Amylin to more easily sort out its diabetes portfolio.
And then the diabetes drug Bydureon, which Lilly was developing with Amylin and Alkermes, was rejected by the Food and Drug Administration.
Worst hit will be Amylin Pharmaceuticals, which developed Bydureon and its predecessor, the twice-a-day Byetta, from a compound found in Gila monster saliva.
应用推荐